> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – January 2012

Loading EJC News Focus video

The combination of targeted agents in hormone-sensitive breast cancer may be the way ahead; results from the CLEOPATRA and BOLERO-2 trials, presented at the recent San Antonio Breast Cancer Symposium (Dec 6-10, 2011), suggest that some combinations may dramatically increase progression-free survival.

Also at the meeting, several studies reported on the role of bisphosphonates in the adjuvant setting, which may resolve previous confusion about which women will benefit.

In this month’s EJC News Focus, Rob Coleman (University of Sheffield, UK), who was at the meeting, discusses the implications of the new data with Helen Saul.